# Public figure use of GLP-1 weight loss medications > Live situation record from CLSTR: https://clstr.news/situations/public-figure-use-of-glp-1-weight-loss-medications > Updated: 2026-08-15T22:58:32.000Z. Sources: 14. Developments: 2. Public figures in the United States and South Korea are increasingly utilizing GLP-1 receptor agonist medications to manage weight and metabolic health. In the United States, actress Chrissy Metz disclosed her use of GLP-1 medication to address health concerns such as perimenopause and family history of obesity. Metz reported that the treatment helped quiet ‘food noise’—described as persistent, intrusive thoughts about food—and provided physical benefits like reduced inflammation and joint pain. Her weight loss has contributed to broader social debates regarding the body positivity movement and the implications of medical weight management. In South Korea, comedian Yoo Min-sang revealed he has started a medically supervised weight loss regimen following clinical warnings regarding his body mass index and metabolic profile. These medications function by mimicking hormones to regulate glycemic control and suppress appetite by targeting the hypothalamus. ## Timeline ### 2026-08-15: GLP-1 weight loss medications used by public figures for metabolic health Celebrities Yoo Min-sang and Chrissy Metz have utilized GLP-1 receptor agonist injections for weight loss and metabolic health management, sparking discussions on medical intervention and body positivity. 3 sources. https://clstr.news/cluster/glp-1-weight-loss-medications-used-by-public-figures-for-metabolic-health ### 2026-08-10: Chrissy Metz reveals use of GLP-1 medication after years of skepticism Actress Chrissy Metz has shared that she began using GLP-1 medication to manage health issues and ‘food noise’ after years of skepticism regarding weight-loss drugs. 11 sources. https://clstr.news/cluster/chrissy-metz-discusses-use-of-glp-1-medication --- Cite as: Public figure use of GLP-1 weight loss medications. CLSTR, https://clstr.news/situations/public-figure-use-of-glp-1-weight-loss-medications